Project Grant R43HL187101
Award Date 8/15/26
Completion Date 8/14/27
Dollars Obligated $330K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55414, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Starlight Cardiovascular, Inc. $499,952 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, to advance commercialization of a catheter-delivered, adjustable percutaneous pulmonary flow restrictor designed to replace surgical pulmonary artery banding in newborns with hypoplastic left heart syndrome and other congenital heart defects. The flow restrictor addresses clinical limitations of current surgical...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart, Lung, and Blood Institute awarded Innovative Design Labs Inc. $1,020,633 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a mannequin product line that improves training in cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) interventions. The recipient will create mannequins representing diverse body types and populations at highest risk for out-of-hospital cardiac arrest, addressing a...
- The National Heart, Lung, and Blood Institute awarded Resuscitation Innovations LLC $396,098 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test an adjustable-pressure impedance threshold device for cardiac arrest resuscitation and post-resuscitation care. The recipient will refine the design of the Adjustable Pressure for Emergency Care (APEC) device, a dual-setting airway device with selectable cracking pressures of -6 and -12 centimeters of...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Nimble Surgical Incorporated $314,362 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop FLEXLOCK, a manually operable anchoring guide catheter designed to simplify transradial complex percutaneous coronary interventions. FLEXLOCK delivers simultaneous active and passive support through an anchoring tip to provide stable coronary access during complex PCI...
- The National Heart, Lung, and Blood Institute awarded Ram Medical Innovations, Inc. $344,740 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop foundational engineering and preclinical data for a coronary sheath stabilization device. The Coronary M-Y Sheath is designed to address limitations in complex percutaneous coronary interventions by providing active stabilization through a proprietary anchoring mechanism that leverages two vascular access...
- The National Heart, Lung, and Blood Institute awarded Coridea, LLC $305,365 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cooled radiofrequency bronchoscopic lung volume reduction technology for severe emphysema patients. The project addresses a clinical gap in lung volume reduction therapy. Current surgical options reach only a fraction of severe emphysema patients: wedge excision LVR surgery is invasive and limits candidate eligibility, while...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Minnesota Healthsolutions Corporation $1,068,096 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and evaluate a prototype novel bladder catheterization device. The device addresses a critical clinical gap in urologic management. Over one million Americans—including more than 250,000 people with spinal cord injury, 120,000 with spina bifida,...